Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

EPH Receptor B4 anticorps

EPHB4 Reactivité: Humain WB, ELISA, IHC Hôte: Souris Monoclonal 5B8F7 unconjugated
N° du produit ABIN969107
  • Antigène Voir toutes EPH Receptor B4 (EPHB4) Anticorps
    EPH Receptor B4 (EPHB4)
    Reactivité
    • 43
    • 34
    • 2
    Humain
    Hôte
    • 44
    • 12
    • 4
    • 1
    Souris
    Clonalité
    • 45
    • 16
    Monoclonal
    Conjugué
    • 31
    • 5
    • 4
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    Cet anticorp EPH Receptor B4 est non-conjugé
    Application
    • 45
    • 34
    • 9
    • 8
    • 4
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
    Purification
    purified
    Immunogène
    Purified recombinant fragment of EphB4 expressed in E. coli.
    Clone
    5B8F7
    Isotype
    IgG2a
    Top Product
    Discover our top product EPHB4 Anticorps primaire
  • Indications d'application
    ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Ascitic fluid containing 0.03 % sodium azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C/-20 °C
    Stockage commentaire
    4°C, -20°C for long term storage
  • Chrencik, Brooun, Recht, Kraus, Koolpe, Kolatkar, Bruce, Martiny-Baron, Widmer, Pasquale, Kuhn: "Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity." dans: Structure (London, England : 1993), Vol. 14, Issue 2, pp. 321-30, (2006) (PubMed).

    Wu, Suo, Risberg, Karlsson, Villman, Nesland: "Expression of Ephb2 and Ephb4 in breast carcinoma." dans: Pathology oncology research : POR, Vol. 10, Issue 1, pp. 26-33, (2004) (PubMed).

  • Antigène
    EPH Receptor B4 (EPHB4)
    Autre désignation
    EphB4 (EPHB4 Produits)
    Synonymes
    anticorps HTK, anticorps MYK1, anticorps TYRO11, anticorps htk, anticorps myk1, anticorps ephB4a, anticorps tyro11, anticorps ephb4b, anticorps MGC130997, anticorps AI042935, anticorps Htk, anticorps MDK2, anticorps Myk1, anticorps Tyro11, anticorps cb646, anticorps ephB4, anticorps rtk5, anticorps EphB-rtk8, anticorps cb417, anticorps rtk8, anticorps EPH receptor B4, anticorps EPH receptor B4 L homeolog, anticorps EPH receptor B4 S homeolog, anticorps Eph receptor B4, anticorps eph receptor B4a, anticorps eph receptor B4b, anticorps EPHB4, anticorps ephb4.L, anticorps ephb4.S, anticorps ephb4, anticorps Ephb4, anticorps ephb4a, anticorps ephb4b
    Sujet

    Description: EPH receptor B4 (EphB4), with 987-amino acid protein (about 108 kDa), belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. The Eph receptor tyrosine kinases and their ligands, the ephrins, regulate numerous biological processes in developing and adult tissues and have been implicated in cancer progression and in pathological forms of angiogenesis. EphB4 acts as a negative regulator of blood vessel branching and vascular network formation, switching the vascularization program from sprouting angiogenesis to circumferential vessel growth. EphB4 and its ligand ephrinB2 express in several kinds of tumor cells and correlate with tumorigenesis. EphB4 is thus a potential candidate as a predictor of disease outcome in several kinds of tumor and as target for novel therapy.

    Aliases: HTK, MYK1, TYRO11

    ID gène
    2050
    HGNC
    2050
    Pathways
    Signalisation RTK
Vous êtes ici:
Support technique